Patents Examined by Raymond J. Henley, III
  • Glycolysis-activating agents for treatment or prevention of disease
    Patent number: 11690841
    Abstract: The present invention relates to glycolysis-activating agents. The present invention also relates to the treatment or prevention of diseases or medical conditions, in particular immune-related diseases or medical conditions. In particular, the present invention also relates to agents for use in the treatment or prevention of a disease or medical condition, which treatment or prevention is mediated via the trafficking of endogenous regulatory T cells (Tregs).
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: July 4, 2023
    Assignee: Queen Mary University of London
    Inventor: Federica Maria Marelli-Berg
  • Characterization of the oral microbiome for the non-invasive diagnosis of Barrett's esophagus
    Patent number: 11684595
    Abstract: The present invention relates to noninvasive microbiome analyses of Barrett's esophagus (BE) patients in which changes in the relative abundance of certain bacteria indicate a disease likelihood or pathogenic state. Additional aspects of the present invention relate to manipulating the microbiome to treat or prevent BE and related conditions. Embodiments also include monitoring for development of disease or monitoring treatment for prevention or elimination of disease states.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: June 27, 2023
    Assignee: The Trustees of Columbia University in the City of New York
    Inventor: Julian Abrams
  • Methods of treating disorders using CSF1R inhibitors
    Patent number: 11679110
    Abstract: Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: June 20, 2023
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Bryan D. Smith, Rodrigo Ruiz Soto, Keisuke Kuida
  • Methods for making and using endoxifen
    Patent number: 11680036
    Abstract: The present disclosure provides industrially scalable methods of making (Z)-endoxifen or a salt thereof, crystalline forms of endoxifin, and compositions comprising them. The present disclosure also provides methods for treating hormone-dependent breast and hormone-dependent reproductive tract disorders.
    Type: Grant
    Filed: December 29, 2022
    Date of Patent: June 20, 2023
    Assignee: ATOSSA THERAPEUTICS, INC.
    Inventors: Steven C. Quay, Yao-Lin Sun, LungHu Wang, ChangJung Wu, ChuanDer Huang
  • Fatty acid synthase inhibitors
    Patent number: 11679111
    Abstract: The present disclosure relates to a method for inhibiting Fatty Acid Synthase (FASN) with a FASN inhibitor, methods for treating cancer and viral infections with a FASN inhibitor, and compounds and compositions inhibiting FASN.
    Type: Grant
    Filed: April 2, 2021
    Date of Patent: June 20, 2023
    Assignees: Duke University, Ohio State Innovation Foundation
    Inventors: Jesse Kwiek, Timothy Haystead, Philip Hughes, Yazan Alwarawrah
  • Anhydrous compositions of mTOR inhibitors and methods of use
    Patent number: 11679101
    Abstract: Disclosed herein are compositions and methods for topical delivery of mTOR inhibitors. In one embodiment, an anhydrous composition includes one or more mTOR inhibitors, one or more solvents, one or more gelling agents, and one or more antioxidants. Also disclosed herein are methods to treat skin disorders using such compositions.
    Type: Grant
    Filed: April 7, 2021
    Date of Patent: June 20, 2023
    Assignee: PALVELLA THERAPEUTICS, INC.
    Inventors: Wesley Harton Kaupinen, Braham Shroot, Simon David Betson, Charles Rodney Greenaway Evans, Marc Barry Brown
  • Oral testosterone non-undecanoate therapy
    Patent number: 11672807
    Abstract: Disclosed are methods and compositions for testosterone replacement therapy, especially for use in administration to hypogonadal males. The methods and compositions employ a fixed dose dosing regimen that does not require titration or dose adjustments and that can provide a therapeutically effective amount of a non-undecanoate testosterone ester while avoiding unacceptably high testosterone levels.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: June 13, 2023
    Inventors: Nachiappan Chidambaram, Satish K. Nachaegari, Mahesh V. Patel, Kilyoung Kim
  • Methods of treating Fabry patients having renal impairment
    Patent number: 11666564
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: February 18, 2022
    Date of Patent: June 6, 2023
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Method for treating rheumatoid arthritis
    Patent number: 11648230
    Abstract: A method for reducing macrophage migration inhibitory factor (MIF or MMIF) cytokine or its biological activity, including the step of administering an isothiocyanate functional surfactant to a patient having a disease or condition wherein MIF cytokine or its biological activity is implicated in the disease or condition.
    Type: Grant
    Filed: December 13, 2020
    Date of Patent: May 16, 2023
    Assignee: THE WILLIAM M YARBROUGH FOUNDATION
    Inventor: Michael E. Silver
  • Composition containing eicosapentaenoic acid alkyl ester, and method for producing same
    Patent number: 11648229
    Abstract: Provided are: a composition containing 96-99 area % of eicosapentaenoic acid alkyl ester, the composition having an arachidonic acid alkyl ester content of 0.7 area % or less, and an eicosapentaenoic-acid-alkyl-ester mono-trans isomer content of 2.5 area % or less; and a method for producing a composition containing a high concentration of eicosapentaenoic acid alkyl ester, the method including performing precision distillation on a composition containing eicosapentaenoic acid alkyl ester, obtained by alkyl esterification of a raw material oil containing eicosapentaenoic acid, under a vacuum of 0.2 Torr or lower and a temperature of 190° C. or lower in the entire column, and performing a concentration treatment on the precision-distilled composition using chromatography.
    Type: Grant
    Filed: October 21, 2020
    Date of Patent: May 16, 2023
    Assignees: NIPPON SUISAN KAISHA, LTD., MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Nobushige Doisaki, Shingo Arato, Takuro Fukae
  • TTP phosphorylation as a biomarker in targeted therapy
    Patent number: 11648251
    Abstract: The present invention relates to a method of determining if a patient is likely to respond to a treatment with a targeted therapy compound selected from protein kinase inhibitors, small molecule inhibitors, and monoclonal antibody-based compounds. The present invention further relates to a method of identifying a targeted therapy compound selected from protein kinase inhibitors, small molecule inhibitors, and monoclonal antibody-based compounds for personalized medicine. The present invention also relates to a method of treatment of cancer in a patient. The present invention also relates to a targeted therapy compound selected from protein kinase inhibitors, small molecule inhibitors, and monoclonal antibody-based compounds for use in a method of treatment of cancer in a patient.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: May 16, 2023
    Assignee: KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE
    Inventor: Khalid S. Abu Khabar
  • Methods of treating Fabry patients having renal impairment
    Patent number: 11642334
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: May 9, 2023
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Use of cannabinoids in the treatment of epilepsy
    Patent number: 11633369
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: August 11, 2022
    Date of Patent: April 25, 2023
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
  • Method for treating infectious diseases with isothiocyanate functional compounds
    Patent number: 11633375
    Abstract: A method for treating an infectious disease, including the step of administering an isothiocyanate functional surfactant to a patient having an infectious disease.
    Type: Grant
    Filed: December 13, 2020
    Date of Patent: April 25, 2023
    Assignee: THE WILLIAM M. YARBROUGH FOUNDATION
    Inventor: Michael E. Silver
  • Pharmaceutical compounds
    Patent number: 11634425
    Abstract: Benzodiazepine derivatives of formula (I): (I) wherein: each of R1 and R2 is independently H or halo; either (i) T is N, Z is C, -a- and -c- are bonds, and -b- and -d- are absent; or (ii) T is C, Z is N, -b- and -d- are bonds, and -a- and -c- are absent; each of R3 and R4 is independently halo, —OR6, —NR6R7—COR8, —C(O)OR8, —CON(R8)2 or —R6; R5 is H or halo; each of R6 and R7 is independently H or a group selected from C1-C6 alkyl, C3-C10 cycloalkyl, C6-C10 aryl, 4- to 10-membered heterocyclyl and 4- to 10-membered heteroaryl, the group being unsubstituted or substituted; R8 is H or C1-C6 alkyl, each R8 being the same or different when two are present; n is 0 or 1; and one of V, W, X and Y is N or CH and the other three are CH; and the pharmaceutically acceptable salts thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.
    Type: Grant
    Filed: June 21, 2022
    Date of Patent: April 25, 2023
    Assignee: PFIZER INC.
    Inventors: George Stuart Cockerill, James Good, Edward James Cochrane
  • Methods of treating Fabry patients having renal impairment
    Patent number: 11633387
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: October 21, 2020
    Date of Patent: April 25, 2023
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods of treating Fabry patients having renal impairment
    Patent number: 11633388
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: April 25, 2023
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Method for treating metastatic prostate cancer
    Patent number: 11633376
    Abstract: A method for treating benign prostatic hyperplasia (BPH), prostatitis, and/or prostate cancer, including the step of administering an isothiocyanate functional surfactant to a patient affected by benign prostatic hyperplasia, prostatitis, and/or prostate cancer.
    Type: Grant
    Filed: December 13, 2020
    Date of Patent: April 25, 2023
    Assignee: THE WILLIAM M. YARBROUGH FOUNDATION
    Inventor: Michael E. Silver
  • Methods of treating Fabry patients having renal impairment
    Patent number: 11622962
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: April 11, 2023
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods for treating heterotopic ossification
    Patent number: 11622959
    Abstract: The invention features dosing regimens and pharmaceutical formulations for oral administration of palovarotene. The dosing regimens can reduce heterotopic ossification, reduce the number of flare-ups, and/or reduce the severity of flare-ups in subjects suffering from fibrodysplasia ossificans progressiva.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: April 11, 2023
    Assignee: Clementia Pharmaceuticals Inc.
    Inventors: Clarissa Desjardins, Donna Roy Grogan, Jeffrey Neal Packman, Mark Harnett